What Orixha does

Orixha is a French DeepTech medical device company founded in 2018 as a spin-off from EnvA (Ecole Nationale Vétérinaire d'Alfort), INSERM, and the Université de Sherbrooke (Canada). The company develops a proprietary Total Liquid Ventilation (TLV) platform called LuncoLive (Lung Conservative Liquid Ventilation), which circulates a perfluorocarbon-based breathable liquid (Liquid2Breathe) through a patient's lungs using a dedicated liquid ventilator. The platform enables both hypothermic TLV (Vent2Cool, cooling to 20–33°C) and normothermic TLV (Vent2Breathe, 36–37°C), with real-time adaptive regulation of liquid volume and pressure via sensors, actuators, and algorithms. Orixha targets the unmet need in Post Cardiac Arrest Syndrome (PCAS), where current therapeutic hypothermia devices take hours to reach the protective 33°C threshold, by cooling the heart and brain in under 15 minutes using the lungs as thermal bio-exchangers.

The company's lead product Vent2Cool is the first medical device ready for ICU use, with 40+ supporting publications, 4 prototype generations, and a worldwide license on the underlying TLV technology from Erganeo. The OverCool first-in-human feasibility study (NCT06798818) was approved by ANSM in September 2024, with patient enrollment underway in 2025 at Hôpital Cochin (Paris) and CHU Angers, and clinical validation targeted to complete by end of 2027. CE Mark is targeted for 2027, with EU commercial launch planned from 2030, targeting 10,000 cardiac arrest patients per year in Europe by 2030 and 3,000 lives saved plus 5,000 reduced neurological sequelae annually by 2031.

Orixha is currently pre-revenue and has raised approximately €17.5M+ across a €2M seed (2021), a €7.5M EIC Accelerator award (2022), a €4M pre-Series A (2024) co-led by EIC Fund and Bpifrance, and a €4M France 2030 grant (2025) for its (L2B)2 industrial reprocessing factory at Plaine de l'Ain. The commercial model will rely on direct enterprise sales of Vent2Cool devices to hospital Cardiac Arrest Centers and ICUs, supplemented by recurring consumable revenue from L2B breathable liquid (enabled by a 4x per-patient cost reduction from the reprocessing factory). Pricing has not been publicly disclosed. A second device, Vent2Breathe for Acute Respiratory Distress Syndrome, is in preclinical development under the LiveResp ANR program.

Name

Orixha

Legal name

ORIXHA

Website

https://orixha.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Orixha is a French DeepTech medical device company developing Total Liquid Ventilation technology. Its lead product Vent2Cool delivers ultra-rapid therapeutic hypothermia for post-cardiac arrest patients in hospital ICUs and cardiac arrest centers across Europe.

Ownership category

akta.pro rank

Product category

Therapeutic Hypothermia Medical Devices

NAICS

Ventilation, Heating, Air-Conditioning, and Commercial Refrigeration Equipment Manufacturing (33341), Air-Conditioning and Warm Air Heating Equipment and Commercial and Industrial Refrigeration Equipment Manufacturing (333415)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC)

akta.pro secondary industries

Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG), Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)

Keywords

• Therapeutic hypothermia devices
• Liquid ventilation technology
• Critical care medical devices
• Cardiac arrest treatment
• Respiratory support devices

Headquarters

HQ city

Maisons-alfort

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Medical Device Sales (Vent2Cool): Orixha plans to commercialize Vent2Cool in EU from 2030 following CE Mark approval (expected 2027). The device will be sold to hospital Cardiac Arrest Centers and ICUs as a therapeutic hypothermia system. The (L2B)2 reprocessing factory (planned commissioning 2028) will enable cost-efficient per-patient pricing by reusing the breathable liquid, supporting broad payer adoption.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Orixha develops and plans to commercialize Vent2Cool, a Total Liquid Ventilation medical device that uses the lungs as thermal bio-exchangers to induce ultra-rapid therapeutic hypothermia (cooling the heart and brain to 33C in under 15 minutes) for patients suffering from Post Cardiac Arrest Syndrome. The system is powered by the proprietary LuncoLive platform and uses Liquid2Breathe (L2B), a perfluorocarbon-based breathable liquid reprocessed via the company's (L2B)2 industrial technology. A second pipeline device, Vent2Breathe, targets respiratory support for acute respiratory distress.

Product overview

Orixha offers a clinical platform based on its proprietary LuncoLive Total Liquid Ventilation technology. The core offering consists of the LuncoLive platform powering two medical devices: Vent2Cool for ultra-rapid therapeutic hypothermia in post-cardiac arrest syndrome, and Vent2Breathe for respiratory support in acute respiratory distress (in development). The system uses Liquid2Breathe (L2B) breathable liquid as a consumable. Orixha is structured as a DeepTech medical device company transitioning from R&D to clinical validation, not as a SaaS or software platform.

Differentiator

Problem solved

Functional benefit

Brands

• LuncoLive: Lung Conservative Liquid Ventilation technology platform - the proprietary TLV technology powering Orixha's medical devices for critical care applications including ultra-rapid hypothermia and respiratory support.
• Vent2Cool
• Vent2Breathe
• Liquid2Breathe (L2B)

Products and services

• LuncoLive Platform

Quantifiable outcome

• Vent2Cool cools heart and brain to 33°C in under 15 minutes vs. several hours for existing hypothermia devices
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• CHU AngerscoreStrategic or Co-development Partner · 1 January 2025CHU Angers is the second leading cardiac arrest center participating in the OverCool clinical trial. Pr Alain Mercat serves as Principal Investigator. The involvement of intensivist and nurse teams from CHU Angers, alongside Hôpital Cochin, supports the completion of the OverCool study by end of 2027.
• Hôpital Cochin (AP-HP Paris)coreStrategic or Co-development Partner · 1 January 2024Hôpital Cochin in Paris is the lead site for the OverCool first-in-human feasibility clinical trial (NCT06798818), approved by ANSM in September 2024. Pr Alain Cariou serves as Principal Investigator. The hospital is one of Europe's leading Cardiac Arrest Centers. OverCool enrollment began in 2025 at this site.
• LiveResp ANR Research ProgramminorStrategic or Co-development Partner · 1 January 2021The LiveResp program (ANR-21-CE19-0033) supports the preclinical proof of concept for TLV in respiratory distress. Partners include EnvA and Hôpital Louis Mourier (AP-HP Paris) alongside Orixha. This program is developing the scientific foundation for Vent2Breathe, Orixha's second medical device.
• Hôpital Louis Mourier (AP-HP Paris)minorStrategic or Co-development Partner · 1 January 2021Hôpital Louis Mourier is a research partner in the LiveResp ANR program alongside Orixha, focusing on preclinical proof of concept for TLV in respiratory distress, which feeds into the Vent2Breathe device development.
• INSERM U955 / Ecole Nationale Vétérinaire d'Alfort (EnvA)coreStrategic or Co-development Partner · 1 January 2018INSERM and EnvA are the original academic institutions behind the LuncoLive technology. Pr Renaud Tissier's INSERM team at EnvA collaborated with Université de Sherbrooke to develop and patent the lung conservative liquid ventilation technology over 10+ years, resulting in 40+ publications and three patents. Orixha was founded as a DeepTech spin-off from these institutions in 2018. Pr Tissier serves as Co-Founder and Chief Medical Officer of Orixha.
• Université de Sherbrooke – Inolivent LabcoreStrategic or Co-development Partner · 1 January 2018The Inolivent Lab at Université de Sherbrooke, Canada, led by Pr Philippe Micheau, developed the first liquid ventilation prototypes (Inolivent 1–3) in the 2000s. This academic collaboration with INSERM/EnvA resulted in the patented LuncoLive technology. Pr Micheau serves as Senior Advisor for IP & Technology at Orixha. Mathieu Nadeau, who designed the first academic prototypes over a decade ago, is Co-Founder and CTO of Orixha.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Hamilton Medical: Hamilton Medical is a leading Swiss manufacturer of ICU ventilators used in critical care settings including post-cardiac arrest patients. As a ventilation incumbent with established clinical workflows and customer relationships, Hamilton represents the type of company Orixha's Vent2Cool must integrate with or compete against in ICU settings.
• ZOLL Medical Corporation: ZOLL (acquired by Asahi Kasei in 2012) is a leading provider of therapeutic hypothermia and targeted temperature management products including the Thermogard XP and IVTM platforms. It is the most established competitor in the post-cardiac arrest cooling space that Vent2Cool targets, with broad hospital penetration and decades of clinical evidence.
• Philips Respironics: Philips is a major manufacturer of hospital ventilators and respiratory care equipment. As a broad incumbent in respiratory care with established hospital channels, Philips represents both a competitor and potential commercial partner for Orixha's liquid ventilation platform in critical care settings.
• Medtronic: Medtronic acquired Covidien's Puritan Bennett ventilator business and has a substantial presence in critical care ventilation. As a $100B+ medical device giant, Medtronic has the resources, clinical relationships, and commercial reach to either partner with or potentially acquire TLV technology to enhance its critical care portfolio.
• Getinge: Getinge (formerly Maquet) is a major ICU equipment manufacturer including mechanical ventilators used in post-cardiac arrest care. As a broad incumbent in critical care ventilation, Getinge has the customer relationships, service infrastructure, and product portfolio breadth that any novel ventilation technology must integrate with or displace.
• Becton Dickinson (BD): BD acquired the Arctic Sun temperature management system (formerly Medivance), one of the leading surface cooling devices used in cardiac arrest and therapeutic hypothermia. As a $20B+ medical device incumbent, BD has the clinical relationships, evidence base, and commercial reach that Vent2Cool would need to displace or complement.
• Drägerwerk: Dräger is a major German manufacturer of anesthesia, ventilation, and critical care equipment including ICU ventilators. As a broad incumbent with strong European hospital penetration, Dräger represents both a potential commercial partner and competitor for any novel ventilation technology targeting European ICUs.

Emerging players

• Vapotherm: Vapotherm develops high-velocity nasal insufflation systems for respiratory support, targeting respiratory distress conditions similar to Orixha's future Vent2Breathe application. As an emerging respiratory support company, Vapotherm represents both an adjacent competitor for the ARDS indication and a comparable company at a similar stage of commercialization.
• Attune Medical: Attune Medical developed the ensoETM, an esophageal cooling device that provides faster and more controlled temperature management than conventional surface cooling. It represents an emerging alternative approach to therapeutic hypothermia that could compete with or complement Vent2Cool's lung-based cooling approach.
• Life Recovery Systems: Life Recovery Systems developed the ThermoSuit, a rapid cooling system that uses ice water immersion to induce therapeutic hypothermia quickly. As an emerging alternative cooling technology, it represents the type of faster-cooling approach that could compete with Vent2Cool's performance differentiation in the post-cardiac arrest market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/OrixhaMed
• YouTubevimeo.com/user130752477
• LinkedInlinkedin.com/company/12652754/admin/feed/posts

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orixha